Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
48.9M
-
Shares change
-
+1.02M
-
Total reported value, excl. options
-
$533M
-
Value change
-
+$12.5M
-
Put/Call ratio
-
0.27
-
Number of buys
-
71
-
Number of sells
-
-56
-
Price
-
$10.91
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2022
156 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2022.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.9M shares
of 62.2M outstanding shares and own 78.64% of the company stock.
Largest 10 shareholders include STATE STREET CORP (3.79M shares), BlackRock Inc. (3.65M shares), FARALLON CAPITAL MANAGEMENT LLC (3.65M shares), RTW INVESTMENTS, LP (3.59M shares), VANGUARD GROUP INC (3.1M shares), JOHNSON & JOHNSON (2.45M shares), MORGAN STANLEY (2.44M shares), Bain Capital Life Sciences Investors, LLC (2.36M shares), CITADEL ADVISORS LLC (2.36M shares), and MARSHALL WACE, LLP (1.45M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.